ArticleInternational medical case reports journal2025
Hepatotoxicity Induced by Adalimumab in Chronic Plaque Psoriasis Patient: A Case Report.
Article in International medical case reports journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Adalimumab is a TNF-α antagonist used to treat psoriasis and rheumatologic conditions; it can rarely cause hepatotoxicity manifesting as elevated liver enzymes. Case Presentation: Here, we present a case of a 24-year-old female with chronic plaque psoriasis with no history of liver disease or any risk factor for liver disease who developed a drug-induced liver injury upon treatment initiation with Adalimumab. This case report highlights the importance of monitoring liver function tests in patients receiving Adalimumab, early recognition, and prompt medication dosage adjustment or discontinuation. Early diagnosis and treatment of chronic plaque psoriasis is critical for improving prognosis, especially in the case of increased risk factors of liver disease due to the administration of Adalimumab. Conclusion: Our case presented a patient with no history of liver disease; however, she developed a drug-induced liver injury. Therefore, this case report is the first to emphasize the need for early recognition of LFTs upon Adalimumab administration, and prompt medication dosage adjustment or discontinuation is essential in patients receiving Adalimumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.